| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/APT.15141 |
| P698 | PubMed publication ID | 30706502 |
| P50 | author | David Wishart | Q27887604 |
| Giada De Palma | Q79778478 | ||
| Rupasri Mandal | Q106388204 | ||
| P2093 | author name string | Ammar Hassanzadeh Keshteli | |
| Guy E Boeckxstaens | |||
| Levinus A Dieleman | |||
| Stephen Vanner | |||
| Premysl Bercik | |||
| Karen L Madsen | |||
| David E Reed | |||
| P2860 | cites work | The human urine metabolome | Q21132532 |
| Cytoscape: a software environment for integrated models of biomolecular interaction networks | Q24515682 | ||
| Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing | Q24570129 | ||
| QIIME allows analysis of high-throughput community sequencing data | Q24616873 | ||
| Functional bowel disorders | Q29620328 | ||
| Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data | Q31157876 | ||
| Comorbid depression and anxiety effects on pregnancy and neonatal outcome | Q33643050 | ||
| Serum Tryptophan Metabolite Levels During Sleep in Patients With and Without Irritable Bowel Syndrome (IBS). | Q33803547 | ||
| Effect of sleep deprivation on the human metabolome | Q33972140 | ||
| The role of mast cells in functional GI disorders. | Q34486007 | ||
| FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial | Q34518185 | ||
| Guidelines on the irritable bowel syndrome: mechanisms and practical management. | Q34626602 | ||
| MetaboAnalyst 3.0--making metabolomics more meaningful | Q35610559 | ||
| Risk of Psychiatric Disorders following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study | Q35723382 | ||
| Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome | Q35865356 | ||
| Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome | Q35867820 | ||
| An investigation of fecal volatile organic metabolites in irritable bowel syndrome | Q36680897 | ||
| Targeted metabolomics profiles are strongly correlated with nutritional patterns in women | Q36718493 | ||
| Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases | Q37454433 | ||
| Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice | Q37632259 | ||
| Colonic metabolites of berry polyphenols: the missing link to biological activity? | Q37801022 | ||
| Recent and potential developments in the analysis of urine: a review. | Q37822091 | ||
| The effect of irritable bowel syndrome on health-related quality of life and health care expenditures | Q37844828 | ||
| Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis | Q37994513 | ||
| Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy | Q38012884 | ||
| Metabolomics as a diagnostic tool in gastroenterology | Q38160492 | ||
| Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'? | Q38234705 | ||
| Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders? | Q38690823 | ||
| Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we? | Q38765085 | ||
| Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome | Q39178305 | ||
| The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis | Q39411374 | ||
| Dietary patterns and prevalence of irritable bowel syndrome in Iranian adults. | Q39669288 | ||
| Bowel Disorders | Q40769741 | ||
| A single night of sleep curtailment increases plasma acylcarnitines: Novel insights in the relationship between sleep and insulin resistance | Q41335080 | ||
| Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by (1)H NMR spectroscopy | Q42871877 | ||
| Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome | Q43244921 | ||
| Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases | Q44314783 | ||
| GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis | Q45103540 | ||
| Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome | Q46431252 | ||
| Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. | Q47942430 | ||
| An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. | Q48516420 | ||
| Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach. | Q50516321 | ||
| Diagnosis: Rome IV criteria for FGIDs - an improvement or more of the same? | Q52815301 | ||
| Irritable bowel syndrome: a clinical review. | Q52962518 | ||
| Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. | Q53595244 | ||
| Differentiating Medicated Patients Suffering from Major Depressive Disorder from Healthy Controls by Spot Urine Measurement of Monoamines and Steroid Hormones. | Q55032429 | ||
| Metabolomics of Fecal Extracts Detects Altered Metabolic Activity of Gut Microbiota in Ulcerative Colitis and Irritable Bowel Syndrome | Q59160042 | ||
| Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues | Q59879866 | ||
| The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress | Q60707901 | ||
| Are cerebrospinal fluid or urinary monoamine metabolite measures stronger correlates of suicidal behavior in depression? | Q71637228 | ||
| Serum fatty acid profile in subjects with irritable bowel syndrome | Q82439681 | ||
| P433 | issue | 6 | |
| P921 | main subject | irritable bowel syndrome | Q838966 |
| biomarker | Q864574 | ||
| metabolomic profile | Q118125738 | ||
| P304 | page(s) | 723-732 | |
| P577 | publication date | 2019-01-31 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers | |
| P478 | volume | 49 |
| Q95285820 | Application of metabolomics to the study of irritable bowel syndrome |
| Q104478693 | Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis |
| Q92669042 | Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply |
| Q92669032 | Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? |
| Q92349882 | Gut Microbial Metabolites and Biochemical Pathways Involved in Irritable Bowel Syndrome: Effects of Diet and Nutrition on the Microbiome |
| Q64993699 | Multi-omics Analysis of Gut Microbiota and Metabolites in Rats With Irritable Bowel Syndrome. |
| Q90714607 | Peroxiredoxin 1 as an inflammatory marker in diarrhea-predominant and postinfectious irritable bowel syndrome |
| Q91117039 | Symptoms of mast cell activation syndrome in functional gastrointestinal disorders |
Search more.